Physiomics PLC Physiomics to present at AACR Annual Meeting
14 Abril 2023 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
14 April 2023
14 April 2023
Physiomics plc
("Physiomics") or ("the Company")
Conference presentation
Physiomics to present at AACR Annual Meeting
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions , is pleased to
announce that it is participating in the American Association for
Cancer Research Annual Meeting 2023, being held on 14-19 April 2023
in Orlando, FL.
The Company will give an oral presentation entitled "Development
and validation of a quantitative systems pharmacology model for
prediction of preclinical efficacy of PARP inhibitors rucaparib and
talazoparib combined with the ATR inhibitor gartisertib (M4344)".
Physiomics is co-authoring the presentation with client Merck
KGaA.
This newly developed quantitative systems pharmacology model,
part of our Virtual Tumour platform, provides a framework that can
be applied to optimise the dosing regimens of PARP and ATR
inhibitor combinations and help with clinical dosing strategy.
The presentation will be given by Dr Nathalie Dupuy, Senior
Biosimulation Scientist, on 18 April 16:07-16:22 EDT (21:07-21:22
BST). The abstract (#5699) is available at the conference website
via this link . A copy of the presentation will be posted on
Physiomics' website at 17:00 EDT (22:00 BST) on the same day at:
www.physiomics.co.uk/resources .
More information about the conference may be found at:
www.aacr.org/meeting/aacr-annual-meeting-2023/
Executive Chairman & CEO, Dr Jim Millen, said : "Being
awarded a talk at a high-profile conference such as AACR is a
testimony to the scientific quality of our team. We are excited to
present publicly for the first time on our collaborative work with
Merck, and we are looking forward to meeting with other attendees
of the conference."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 100 projects, involving over 50 targets and
75 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUBWCUPWGAW
(END) Dow Jones Newswires
April 14, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
